Schizophrenia is a chronic neuropsychiatric syndrome that significantly impacts daily
function and quality of life. All of the available guidelines suggest a combined treatment …

All antipsychotics currently used in clinic block D2 dopamine receptors. Trace amine-
associated receptor 1 is emerging as a new therapeutic target for schizophrenia and several …

Abstract Objective Metabolic Syndrome, which can be induced or exacerbated by current
antipsychotic drugs (APDs), is highly prevalent in schizophrenia patients. Recent preclinical …

The existing available antipsychotics have failed to manage the cognitive impairment of
schizophrenia and induced a number of seriously undesirable effects. Trace amine …

A large portion of the human GPCRome is still in the dark and understudied, consisting even
of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion …

Currently, metabolic syndrome treatment includes predominantly pharmacological symptom
relief and complex lifestyle changes. Trace amines and their receptor systems modulate …

Trace amine-associated receptor 1 (TAAR1) is an attractive target for the design of
innovative drugs to be applied in diverse pharmacological settings. Due to a non-negligible …

Introduction Psychiatric disorders are a leading cause of disability worldwide, calling for an
urgent need for new treatments, early detection, early intervention, and precision medicine …

The search for novel effective TAAR1 ligands continues to draw great attention due to the
wide range of pharmacological applications related to TAAR1 targeting. Herein, molecular …

A major effort of the pharmaceutical industry has been to identify and market drug treatments
that are effective in ameliorating the symptoms of psychotic illness but without the limitations …